Comparison study of metformin versus insulin in the treatment of gestational diabetes during pregnancy

Pratibha Nanda; Shashi L. Kabra; Richa Madaan; Priya

doi:10.18203/2320-1770.ijrcog20230823

Authors

Pratibha Nanda Department of Obstetrics and Gynecology, Deen Dayal Upadhyay Hospital, New Delhi, India
Shashi L. Kabra Department of Obstetrics and Gynecology, Deen Dayal Upadhyay Hospital, New Delhi, India
Richa Madaan Department of Obstetrics and Gynecology, Deen Dayal Upadhyay Hospital, New Delhi, India
Priya Department of Obstetrics and Gynecology, Deen Dayal Upadhyay Hospital, New Delhi, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20230823

Keywords:

Diabetes mellitus, Gestational diabetes mellitus, Metformin pregnancy

Abstract

Background: Gestational diabetes was traditionally treated with insulin. Metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes. This study aimed to analyze and compare insulin and metformin in the treatment of gestational diabetes and to compare their effects on the pregnancy outcomes.

Method: This comparative prospective observational study was conducted at Deen Dayal Upadhyay Hospital, New Delhi, a tertiary care teaching hospital. The data was collected over a period of 15 months (April 2021 till June 2022). So pregnant females in the age group 18-45 years with 20-30 weeks period of gestation, are diagnosed with gestational diabetes as per the diabetes in pregnancy India (DIPSI). The study group was divided into 2 groups of 40 each, one receiving oral metformin and the other group receiving insulin for treatment.

Results: Metformin was found to be a better drug in controlling blood sugars vis a vis insulin in our study. GDM patients controlled on insulin were found to be associated with; higher weight gain, higher incidence of neonatal hypoglycemia, hyperinsulinemia and higher and longer ICU admission

Conclusions: Metformin was better in controlling blood sugar in GDM than insulin, with better neonatal outcome.

Metrics

Metrics Loading ...

References

Mukhtar MH, El‑Emshay HM, Alamodi HS, Nasif WA. The Activity of Serum 8‑Iso‑Prostaglandin F2α as oxidative stress marker in patients with diabetes mellitus type 2 and associated dyslipidemic hyperglycemia. J Diab Mellitus. 2016;6:318.

Saravanan P. Diabetes in pregnancy working group; maternal medicine clinical study group; royal college of obstetricians and gynaecologists, UK. Gestational diabetes: Opportunities for improving maternal and child health. Lancet Diab Endocrinol. 2020;8:793‑800

Hamid AN, Abd El-Gayed AM, Seif-Elnasr IA, Soliman MH. Comparison the efficacy and safety between Insulin and Metformin in gestational diabetes mellitus management. Menoufia Med J. 2019;32(4): 1376.

Ghomian N, Vahed SH, Firouz S, Yaghoubi MA, Mohebbi M, Sahebkar A. The efficacy of metformin compared with insulin in regulating blood glucose levels during gestational diabetes mellitus: a randomized clinical trial. J Cellular Physiol. 2019; 234(4):4695-701.

Khan RM, Mukhtar A, Khawar A. Comparison of metformin with insulin in the management of gestational diabetes. Med Forum. 2017;28(11):105-9.

Picón-César MJ, Molina-Vega M, Suárez-Arana M, González-Mesa E, Sola-Moyano AP, Roldan-López R, et al. Metformin for gestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes: randomized prospective trial. Am J Obstet Gynecol. 2021;225(5):517.

Mohebbi M, Sahebkar A. FIGO initiative on gestational diabetes. Int J Gynecol Obstet. 2015;131: S173-211.